Rubra Medicaments Ltd - 531099 - Outcome of Board Meeting
Appointment of Mr. Gopal Sahu as Independent Director of the Company.11-06-2019
11-06-2019
RUBRA MEDICAMENTS LTD. - 531099 - Board Meeting Intimation for Appointment Of Mr. Gopal Sahu As Independent Director Of The Company
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/06/2019 ,inter alia, to consider and approve Appointment of Mr. Gopal Sahu as Independent Director of the Company04-06-2019
RUBRA MEDICAMENTS LTD. - 531099 - Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report Sr. No. Particulars Details 1Period for which the report has been issued 31/03/2019 2Date of Report24/05/2019 3 Name of the Certifying Firm Maithili Nandedkar and Associates 4 Name of the Certifying Individual Maithili Nandedkar 5Membership TypeFCS 6 Membership Number 8242 7 CP No. 9307 8 Whether any observations/qualification reported by the Secretarial Auditor ? NO24-05-2019
RUBRA MEDICAMENTS LTD. - 531099 - Outcome of Board Meeting
Audited financial result for the year ended March 31, 201924-05-2019
Rubra Medicaments Ltd - 531099 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayRUBRA MEDICAMENTS LTD. 2CINL33100TG1991PLC013266 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: PRITI PRAMOD SURTI Designation: Company Secretary EmailId: rubraltd@gmail.com Name of the Chief Financial Officer: ABHA RAJESH KAPOOR Designation: Director (Finance) and CFO EmailId: rubraltd@gmail.com Date: 22/05/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.22-05-2019
RUBRA MEDICAMENTS LTD. - 531099 - Board Meeting Intimation for Adoption Of Standalone Audited Financial Result Of The Company For The Quarter And Year Ended March 31, 2019.
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2019 ,inter alia, to consider and approve Adoption of Standalone Audited Financial Result of the Company for the Quarter and Year ended March 31, 2019.14-05-2019
RUBRA MEDICAMENTS LTD. - 531099 - Board Meeting Intimation for Considering Status Of Warrants Allotted To Strategic Investor.
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/04/2019 ,inter alia, to consider and approve status of warrants allotted to strategic investor.18-04-2019
RUBRA MEDICAMENTS LTD. - 531099 - Compliance Certificate For The Half Year Ended March 31, 2019
Compliance Certificate For The Half Year Ended March 31, 201917-04-2019